Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Menopause, a natural process in aging women, involves permanently ceasing menstrual periods for 12 months. A deficiency in estrogen causes this cessation and is not linked to any pathological condition. As women age, the number of ovarian follicles they possess decreases. The decline in granulosa cells, the primary producers of estradiol and inhibin, occurs in the ovary. This reduction leads to an absence of inhibition on gonadotropins, resulting in elevated production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The increase in FSH levels tends to be more pronounced than LH due to LH’s faster clearance from the bloodstream. The decrease in estrogen levels disrupts the hypothalamic-pituitary-ovarian axis, leading to a lack of endometrial development. Consequently, menstrual cycles become irregular before eventually ceasing altogether. It can be induced by surgical procedures like a hysterectomy with bilateral oophorectomy or by treatments for certain medical conditions such as endometriosis, breast cancer (using antiestrogens), and other cancers (due to chemotherapy medications). After menopause, the most prominent symptoms include genitourinary issues like vulvovaginal atrophy, dryness, and lower urinary tract problems such as urinary frequency, urgency, and nocturia. The core criteria for identifying menopause rely on the menstrual cycle, supported by laboratory tests. The female reproductive cycle is categorized into three phases: reproductive, menopause transition, and post-menopause. If left untreated, vasomotor symptoms usually fade after an average period of about 7.4 years.
• Premature natural menopause occurs before age 40, while early menopause occurs between 40 and 45. Roughly 10% of women experience menopause before age 45, 1.9% before 40, and 7.3% between 40 and 45. Considering the average life expectancy of 81 years for women in the US, up to 40% of their lives will be spent in the postmenopausal phase.

Thelansis’s “Menopause Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menopause treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Menopause across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Menopause Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Menopause – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033